These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 11099897

  • 21. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 22. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ.
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [Abstract] [Full Text] [Related]

  • 23. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S.
    Cochrane Database Syst Rev; 2005 Oct 19; (4):CD004450. PubMed ID: 16235363
    [Abstract] [Full Text] [Related]

  • 24. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM, Taher AT.
    Hemoglobin; 2011 Oct 19; 35(5-6):565-73. PubMed ID: 21910602
    [Abstract] [Full Text] [Related]

  • 25. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
    Collins AF, Fassos FF, Stobie S, Lewis N, Shaw D, Fry M, Templeton DM, McClelland RA, Koren G, Olivieri NF.
    Blood; 1994 Apr 15; 83(8):2329-33. PubMed ID: 8161801
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ.
    Expert Opin Drug Saf; 2010 Jul 15; 9(4):633-41. PubMed ID: 20553089
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ, Brunskill SJ, Doree C, Williams S, Howard J, Hyde CJ.
    Cochrane Database Syst Rev; 2007 Jul 18; (3):CD004839. PubMed ID: 17636775
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects.
    Kontoghiorghes GJ, Pattichis K, Neocleous K, Kolnagou A.
    Curr Med Chem; 2004 Aug 18; 11(16):2161-83. PubMed ID: 15279556
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 18; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 37. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
    Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, Sheppard L.
    Br Med J (Clin Res Ed); 1987 Dec 12; 295(6612):1509-12. PubMed ID: 3122880
    [Abstract] [Full Text] [Related]

  • 38. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
    Hemoglobin; 2008 Dec 12; 32(1-2):17-28. PubMed ID: 18274979
    [Abstract] [Full Text] [Related]

  • 39. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Dec 12; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.